Royalty Pharma
Royalty Pharma plc, headquartered in the United States, is a leading player in the biopharmaceutical industry, specialising in the acquisition of revenue-generating pharmaceutical royalties. Founded in 1996, the company has established itself as a pioneer in the royalty financing model, enabling innovation in drug development while providing capital to biopharmaceutical companies.
With a diverse portfolio that includes royalties from some of the world's most successful therapies, Royalty Pharma stands out for its unique approach to funding and supporting drug development. The company operates primarily in North America and Europe, positioning itself as a key partner in the life sciences sector. Notable achievements include a robust market presence and a commitment to advancing healthcare through strategic investments in transformative therapies.
-12 vs industry average
Royalty Pharma’s score of 26 is higher than 50% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Part of the Sustainability team at Royalty Pharma?
- Control how your company's emission story is told
- Respond to customers efficiently
- See who's viewing your profile
Industry Intensity
Pharmaceutical Preparation Manufacturing has below-average carbon intensity
Industry performance
The Pharmaceutical Preparation Manufacturing industry has reduced its overall emissions by 19% since 0
Emissions trajectory 2020 – 2027
Reported emissions
Scope 3 accounts for ••• of total emissions.
Royalty Pharma's reported carbon emissions
In 2024, Royalty Pharma reported carbon emissions of approximately 23,266,000 kg CO2e, all of which fall under Scope 3 emissions, specifically from investments. This represents a decrease from the previous year's emissions of about 32,002,000 kg CO2e in 2023. The company has not disclosed any Scope 1 or Scope 2 emissions data, and there are no reported reduction targets or climate pledges at this time. The emissions data is sourced directly from Royalty Pharma plc, with no cascading from a parent or related organization. The company is actively engaged in monitoring its carbon footprint, although it currently lacks specific reduction initiatives or commitments. As a leading player in the pharmaceutical sector, Royalty Pharma's focus on emissions transparency is crucial for aligning with industry standards and addressing climate change impacts.
Unlock detailed emission data
Access structured emission data, company specific factors and auditable source documents
Royalty Pharma’s Climate Goals (2030 & 2050)
No climate goals have been disclosed for Royalty Pharma yet.
Scope 3 top emissions categories
1 of 15 categories disclosedSee all scope 3 categories
Already have an account? Sign in now
Emissions comparison with industry peers
View similar organisations
Royalty Pharma
Usage policy
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Where does DitchCarbondata come from?
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn moreCurious to see your top suppliers emissions?
Book a demo for a pilot project